Overview
The main purpose of this study is to identify important treatment attributes for post-radical cystectomy (RC) treatment for participants with MIBC (Muscle-Invasive Bladder Cancer) and assess the relative importance of treatment attributes for post-RC treatment in Japan.
Eligibility
Inclusion Criteria:
- Must reside in Japan and able to speak/read Japanese for the interview/survey
- Must have a clinical diagnosis of Muscle-invasive bladder cancer (MIBC):
- ypT2-ypT4a or ypN+ MIBC, with prior neoadjuvant cisplatin chemotherapy and underwent radical cystectomy
- pT3-pT4a or pN+ MIBC, without prior neoadjuvant cisplatin chemotherapy and underwent radical cystectomy
- Must not have received any treatment related to MIBC after radical cystectomy
Exclusion Criteria:
- Determined by the physician as being unsuitable for the study (e.g. having any clinically significant psychiatric disorder, cognitive impairment, or having difficulty with communicating in Japanese)
- Confirmed diagnosis of other primary cancers at the time of obtaining consent
- Current participation in a MIBC clinical trial